AbbVie’ Skyrizi (risankizumab) Receives CHMP’s Positive Opinion for the Treatment of Adults with Active Psoriatic Arthritis in the EU
Shots:
- The opinion was based on the P-III KEEPsAKE-1 & 2 studies evaluate Skyrizi (150mg, SC) vs PBO in adults with active PsA who had an inadequate response or were intolerant to biologic therapy & non-biologic DMARDs
- The trial met its 1EPs of ACR20 response @24wks. The 2EPs also met that include improvements in clinical manifestations of PsA i.e., skin clearance, 90% improvement in PASI 90, physical function as measured by HAQ-DI & MDA @24wks., efficacy & safety profile was consistent with the profile observed ~24wks.
- If approved by the EC, therapy will mark the 2nd indication in the EU. The MAA will be valid in all member states of the EU, Iceland, Liechtenstein, Norway & Northern Ireland
Click here to read the full press release/ article | Ref: AbbVie | Image: The Street